title: Strength and endurance training in the treatment of lung cancer patients in stages IIIA/IIIB/IV.
abstract: OBJECTIVE
  This randomized controlled trial tested the effects of a specially designed strength and endurance training on the independence and quality of life in lung cancer patients in stages IIIA/IIIB/IV during palliative chemotherapy.
  
  
  METHODS
  Between August 2010 and December 2011, 46 patients were randomized into two groups receiving either conventional physiotherapy or special physiotherapeutic training. The Barthel Index served as primary endpoint. The secondary endpoints were the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ C-30/LC-13) questionnaire, the 6-Minute Walk Test (6MWT), stair walking, the Modified Borg Scale, and muscle strength. Nonparametrical data were analyzed with the Wilcoxon and Mann-Whitney U test. For parametric, data student t tests were used. A p value of ≤.05 was accepted.
  
  
  RESULTS
  Twenty-nine patients completed the trial (Intervention group (IG), n = 18; control group (CG), n = 11). Significant differences were detectable in the Barthel Index (IGmean = 92.08; CGmean = 81.67; p = .041), in single scores of the EORTC QLQ C-30/LC-13 questionnaire (physical functioning, p = .025; hemoptysis, p = .019; pain in arms or shoulder, p = .048; peripheral neuropathy, p = .050; cognitive functioning, p = .050), in the 6MWT, stair walking, strength capacity, and in the patient's dyspnoea perception during submaximal walking activities (IG > CG).
  
  
  CONCLUSIONS
  According to these findings, lung cancer patients should receive enhanced physical activity intervention during palliative chemotherapy.
authors.affiliation: Department of Internal Medicine, Hematology and Oncology, Vivantes Clinic Neukoelln, Rudower Strasse 48, 12351, Berlin, Germany.
authors.forename: C C
authors.initials: CC
authors.lastname: Henke
authors.forename: J
authors.initials: J
authors.lastname: Cabri
authors.forename: L
authors.initials: L
authors.lastname: Fricke
authors.forename: W
authors.initials: W
authors.lastname: Pankow
authors.forename: G
authors.initials: G
authors.lastname: Kandilakis
authors.forename: P C
authors.initials: PC
authors.lastname: Feyer
authors.forename: M
authors.initials: M
authors.lastname: de Wit
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015444:Exercise / Q000502:physiology; D005081:Exercise Therapy / Q000379:methods*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D053580:Muscle Strength / Q000502:physiology; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010807:Physical Endurance / Q000502:physiology*; D011446:Prospective Studies; D011788:Quality of Life; D011795:Surveys and Questionnaires; D016138:Walking / Q000502:physiology
chemical_list: D009944:Organoplatinum Compounds